Literature DB >> 7639324

Coexpression of transforming growth factor-alpha and épidermal growth factor receptor in capillary hemangioblastomas of the central nervous system.

G Reifenberger1, J Reifenberger, T Bilzer, W Wechsler, V P Collins.   

Abstract

The expression of epidermal growth factor receptor (EGFR) and the pre-pro form of one of its ligands, transforming growth factor-alpha (TGF-alpha), was studied by Northern blotting in a series of 14 capillary hemangioblastomas of the central nervous system. A constant coexpression of EGFR and pre-pro-TGF-alpha mRNAs was found. Immunocytochemical investigation of an extended series of 51 capillary hemangioblastomas revealed that the stromal cells in these tumors showed immunoreactivity with monoclonal antibodies to EGFR and TGF-alpha. Analysis of gene dosage by Southern blotting in 20 tumors indicated a normal gene copy number of EGFR and TGF alpha in all cases. Our findings suggest that autocrine and/or juxtacrine growth stimulation via the EGFR may contribute to tumor growth in capillary hemangioblastomas.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7639324      PMCID： PMC1869821     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  30 in total

1.  Transmembrane TGF-alpha precursors activate EGF/TGF-alpha receptors.

Authors:  R Brachmann; P B Lindquist; M Nagashima; W Kohr; T Lipari; M Napier; R Derynck
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

2.  Infection with a TGF-alpha retroviral vector transforms normal mouse mammary epithelial cells but not normal rat fibroblasts.

Authors:  M L McGeady; S Kerby; V Shankar; F Ciardiello; D Salomon; M Seidman
Journal:  Oncogene       Date:  1989-11       Impact factor: 9.867

3.  Hemangioblastomas of the central nervous system. A 10-year study with special reference to von Hippel-Lindau syndrome.

Authors:  H P Neumann; H R Eggert; K Weigel; H Friedburg; O D Wiestler; P Schollmeyer
Journal:  J Neurosurg       Date:  1989-01       Impact factor: 5.115

4.  Histogenesis of stromal cells in cerebellar hemangioblastomas. An immunohistochemical study.

Authors:  I Becker; W Paulus; W Roggendorf
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

5.  The TGF-alpha precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction.

Authors:  S T Wong; L F Winchell; B K McCune; H S Earp; J Teixidó; J Massagué; B Herman; D C Lee
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

6.  A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor.

Authors:  T S Frank; J Q Trojanowski; S A Roberts; J J Brooks
Journal:  Mod Pathol       Date:  1989-11       Impact factor: 7.842

7.  Epidermal growth factor receptor gene analysis in renal cell carcinoma.

Authors:  L G Gomella; P Anglard; E R Sargent; C N Robertson; A Kasid; W M Linehan
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

8.  Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue.

Authors:  J H Mydlo; J Michaeli; C Cordon-Cardo; A S Goldenberg; W D Heston; W R Fair
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

9.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

Authors:  P P Di Fiore; J H Pierce; T P Fleming; R Hazan; A Ullrich; C R King; J Schlessinger; S A Aaronson
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

10.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330
View more
  11 in total

Review 1.  Roles of transforming growth factor-alpha and related molecules in the nervous system.

Authors:  C J Xian; X F Zhou
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

2.  Neurologic manifestations of von Hippel-Lindau disease.

Authors:  John A Butman; W Marston Linehan; Russell R Lonser
Journal:  JAMA       Date:  2008-09-17       Impact factor: 56.272

3.  Ocular manifestations of von Hippel-Lindau disease: clinical and genetic investigations.

Authors:  Emily Ying Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2005

4.  Overexpression and activation of epidermal growth factor receptor in hemangioblastomas.

Authors:  Gregory J Chen; Matthias A Karajannis; Elizabeth W Newcomb; David Zagzag
Journal:  J Neurooncol       Date:  2010-02-22       Impact factor: 4.130

5.  Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.

Authors:  Jiabin An; Matthew B Rettig
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.

Authors:  Lisa R Rogers; Patricia LoRusso; Paul Nadler; Ghaus Malik; Anthony Shields; William Kaelin
Journal:  J Neurooncol       Date:  2010-06-04       Impact factor: 4.130

7.  Pathological and Clinical Features and Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease.

Authors:  Hiroshi Kanno; Natsuki Kobayashi; Satoshi Nakanowatari
Journal:  J Kidney Cancer VHL       Date:  2014-08-05

8.  Overexpression of EGFR and TGFα in von Hippel-Lindau-Related Central Nervous System Hemangioblastomas.

Authors:  Zhen Liu; Liang Li; Zhiqiang Yi; Hongzhou Duan; Runchun Lu; Chunwei Li; Jingcheng Zhou; Kan Gong
Journal:  Front Oncol       Date:  2020-05-05       Impact factor: 6.244

9.  Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis.

Authors:  Ruty Mehrian-Shai; Michal Yalon; Itai Moshe; Iris Barshack; Dvorah Nass; Jasmine Jacob; Chen Dor; Juergen K V Reichardt; Shlomi Constantini; Amos Toren
Journal:  BMC Genomics       Date:  2016-01-14       Impact factor: 3.969

Review 10.  Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas.

Authors:  Christ Ordookhanian; Paul E Kaloostian; Samer S Ghostine; Philippe E Spiess; Arnold B Etame
Journal:  J Kidney Cancer VHL       Date:  2017-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.